AuthorisedTherapeutic exploratory (Phase II)Interventional

Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

This study, called ARTIST-CKD, is researching a new medicine called Survodutide for adults with Chronic Kidney Disease (CKD). We want to find out if Survodutide can help reduce the amount of a protein called albumin in your urine. High levels of albumin in the urine can be a sign that the kidneys aren't working as well as they should. The study will last about 40 weeks and compare Survodutide to a dummy treatment (placebo). We will also look at how the treatment might affect other health markers like kidney function, body weight, and blood pressure. This is an early-stage study to explore the potential benefits of this new treatment.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Universitair Medisch Centrum Groningen

Enrolment target

Start

21 Apr 2026

Chronic Kidney Disease

What is this study about?

This study, called ARTIST-CKD, is looking into a new medicine called Survodutide for people who have long-term kidney problems, known as Chronic Kidney Disease (CKD). Our main goal is to see if Survodutide can lower the amount of a protein called albumin that is found in your urine. Having too much albumin in your urine suggests that your kidneys might not be filtering your blood as well as they should be, and reducing it could be a sign that the treatment is helping.

We'll be comparing Survodutide with a 'placebo', which looks exactly like the study medicine but contains no active drug. This helps us understand if any changes we see are truly due to Survodutide or if they would have happened anyway. We'll also be checking various other health measures, like how well your kidneys are working overall, your body weight, and blood pressure, to get a full picture of the treatment's effects.

This is an early-stage study (Phase II), which means we're exploring if this treatment is safe and if it shows promise in helping people with CKD. The results of this study will help us decide if Survodutide should be studied further in larger trials.

Key takeaways

This study is testing a new medicine, Survodutide, for Chronic Kidney Disease (CKD).
It aims to see if the medicine reduces protein in the urine, a sign of kidney health.
Participants will receive either the active medicine or a dummy treatment (placebo).
The study involves regular clinic visits, tests, and lasts about 40 weeks.
It's an early-stage study to explore the potential of this new treatment.
Taking part could help future understanding and treatments for CKD.

Who may be eligible?

To join this study, you need to be an adult, aged 18 or over. This study is open to both men and women.

There will be other, more detailed health checks to make sure the study is right for you and that you meet all the necessary medical requirements. These might include specific kidney test results or other health conditions.

A doctor involved in the study will discuss all the specific criteria with you to see if you can take part safely.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have Chronic Kidney Disease (CKD)?
Are you able to attend regular clinic appointments for about 40 weeks?
Are you comfortable with receiving either the new medicine or a placebo?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would be given either the new medicine, Survodutide, or a 'dummy' medicine (placebo). You wouldn't know which one you are taking.

During the study, you would have regular visits to the clinic over approximately 40 weeks. These visits would involve various assessments, such as urine tests to measure protein levels, blood tests to check kidney function, and measurements of your weight and blood pressure. Some participants would also have more detailed tests like special kidney function measurements and MRI scans to look at body fat.

There will be a main treatment period, followed by a short period towards the end where you would stop taking the study medicine, so we can see how your body responds.

Potential risks and benefits

Taking part in this study may or may not directly benefit your health, as it's an early-stage investigation into a new treatment. However, your participation could help researchers learn more about Chronic Kidney Disease and potentially lead to new treatments that help others in the future. As with any medicine, there may be potential side effects or risks, which will be fully explained to you before you decide to join. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany
—
Unverified
Spain
—
Unverified
Netherlands

Common questions

What is Chronic Kidney Disease (CKD)?

CKD means your kidneys aren't working as well as they should to filter your blood over a long time.

What is albumin in urine?

Albumin is a protein. Finding it in your urine can be a sign of kidney damage.

What is a 'placebo'?

A placebo is a 'dummy' treatment that looks like the real medicine but contains no active drug. It helps us see if the medicine really works.

Will I know if I'm getting the active medicine or the placebo?

No, you won't know whether you are getting the active medicine or the placebo until the study is over. This is to ensure fair and accurate results.

How long will the study last?

The study will last for approximately 40 weeks, including follow-up visits.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.